Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

NCT03530293 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT03530293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03530293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Terminated
Start date
April 17, 2018
Completion date
July 16, 2019
Enrollment
81 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

tourette syndrome